Journal of Immunological Techniques & Infectious Diseases ISSN: 2329-9541

Reach Us +1 2097300872
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article, J Immunol Tech Infect Dis Vol: 4 Issue: 1

Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis

Subhajit Dasgupta1* and Mausumi Bandyopadhyay2
1Department of Microbiology, Immunology and Department of Biochemistry, Saint James School of Medicine, Albert Lake drive, The Quarter, A-I-2640, P.O Box 318, Anguilla BWI, Anguilla
2Biological Sciences, Trident Technical College, North Charleston, South Carolina 29406, USA
Corresponding author : Subhajit Dasgupta
Department of Microbiology, Immunology, Saint James School of Medicine, Albert Lake Drive, The Quarter, P.O Box 318, A-I-2640, Anguilla BWI, Anguilla
Tel: +1-264-497-5125
E-mail: [email protected]
Received: November 19, 2014 Accepted: January 15, 2015 Published: January 19, 2015
Citation: Subhajit D, Mausumi B (2015) Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis. J Immunol Tech Infect Dis 4:1. doi:10.4172/2329-9541.1000131

Abstract

Prospect of CD52 Targeted Alemtuzumab in Treatment of CNS Demyelination in Multiple Sclerosis

The choice of humanized monoclonal antibody is a novel therapeutic approach for autoimmune relapsing remitting multiple sclerosis (RRMS). In addition to anti-alpha-4 integr in monoclonal antibody Natalizumab, introduction of CAMPATH-1 (Alemtuzumab) is a fairly new approach in MS research and clinical trials. The uniqueness of this monoclonal antibodyis that it depletes CD52 marker expressing circulatory T and B cells including monocytes and dendritic cells. However, it has no impact on progenitor cells. Thus, the use of Alemtuzumab has gained importance in delaying rejection in allograft during transplantation.

Keywords: Multiple sclerosis; CD52; Lymphocytes; Monoclonal antibody; Alemtuzumab

Track Your Manuscript

Share This Page

Media Partners